DRREDDY - Fundamental Analysis: Financial Health & Valuation
Back to ListFundamental Rating: 4.2
| Stock Code | DRREDDY | Market Cap | 1,10,417 Cr. | Current Price | 1,323 ₹ | High / Low | 1,380 ₹ |
| Stock P/E | 23.8 | Book Value | 378 ₹ | Dividend Yield | 0.60 % | ROCE | 25.8 % |
| ROE | 20.3 % | Face Value | 1.00 ₹ | DMA 50 | 1,267 ₹ | DMA 200 | 1,257 ₹ |
| Chg in FII Hold | -1.20 % | Chg in DII Hold | 0.28 % | PAT Qtr | 90.6 Cr. | PAT Prev Qtr | 387 Cr. |
| RSI | 59.5 | MACD | 18.8 | Volume | 12,89,421 | Avg Vol 1Wk | 26,07,976 |
| Low price | 1,121 ₹ | High price | 1,380 ₹ | PEG Ratio | 0.49 | Debt to equity | 0.13 |
| 52w Index | 78.0 % | Qtr Profit Var | -89.3 % | EPS | 55.6 ₹ | Industry PE | 30.1 |
📊 Dr. Reddy’s Laboratories (DRREDDY) demonstrates strong fundamentals with ROE (20.3%) and ROCE (25.8%), supported by low debt-to-equity (0.13). EPS of ₹55.6 reflects robust earnings power, and dividend yield of 0.60% adds shareholder value. Quarterly PAT declined sharply (387 Cr → 90.6 Cr, -89.3%), raising concerns about earnings volatility, though long-term efficiency remains intact. Valuation is fair with P/E (23.8) compared to industry average (30.1), while PEG ratio (0.49) suggests attractive growth-adjusted value. Technicals show bullish momentum with RSI (59.5), MACD (18.8), and price trading above both 50 DMA (1,267 ₹) and 200 DMA (1,257 ₹).
🎯 Entry Zone: 1,250 ₹ – 1,280 ₹ (near DMA support)
📌 Long-Term Holding: Suitable for accumulation with a 3–5 year horizon. Strong fundamentals justify holding, though short-term earnings volatility warrants cautious exposure. Upside potential exists toward 1,350–1,380 ₹ if profitability stabilizes.
Positive
- Strong ROE (20.3%) and ROCE (25.8%) highlight efficiency.
- Low debt-to-equity (0.13) ensures financial resilience.
- EPS of ₹55.6 supports earnings visibility.
- Valuation attractive with P/E (23.8) below industry average (30.1).
- DII holdings increased (+0.28%), showing domestic institutional confidence.
Limitation
- Quarterly PAT decline (-89.3%) highlights earnings weakness.
- FII holdings decreased (-1.20%), showing reduced foreign investor confidence.
- Dividend yield of 0.60% is modest compared to peers.
Company Negative News
- Sharp quarterly profit decline raises concerns about short-term performance.
- Reduced foreign institutional inflows (-1.20%).
Company Positive News
- Strong efficiency metrics with high ROE and ROCE.
- DII inflows (+0.28%) reflect domestic institutional support.
- Valuation remains attractive relative to industry peers.
Industry
- Industry P/E (30.1) is higher than DRREDDY’s 23.8, suggesting fair valuation.
- Pharmaceutical sector remains resilient, supported by global demand for APIs and specialty formulations.
Conclusion
⚡ DRREDDY is fundamentally strong with efficient capital use and low debt. Entry around 1,250–1,280 ₹ offers favorable risk-reward. Long-term holding is justified with cautious accumulation, though short-term earnings volatility limits immediate upside. Partial profit booking near 1,350–1,380 ₹ is advisable, with exit below 1,240 ₹ on heavy volume.
This structured HTML report captures Dr. Reddy’s strong fundamentals and fair valuation while highlighting its short-term earnings volatility. If you’d like, I can extend this into a peer benchmarking overlay against other pharma players like Sun Pharma or Cipla to highlight relative positioning. Would you like me to prepare that next?